I-labeled anti-CEA monoclonal antibody injected intrasplenically has better effects on inhibiting liver metastasis from human colonic adenocarcinoma than that through tail vein in nu/nu mice model.
Objective To summarize our experience in the diagnosis and treatment of malignant pancreatic endocrine tumour. Methods We retrospectively reviewed 36 cases of malignant pancreatic endocrine tumours in our hospital fro...Objective To summarize our experience in the diagnosis and treatment of malignant pancreatic endocrine tumour. Methods We retrospectively reviewed 36 cases of malignant pancreatic endocrine tumours in our hospital from July 1987 to April 2002, and summarized its clinical features. Results Liver metastasis was the main malignant manifestation of malignant pancreatic endocrine tumours (incidence rate 72.2%). Removals of primary lesion and isolated hepatic metastatic lesion were means of curative therapy. Interventional chemotherapy was an important adjuvant treatment. Conclusion Comprehensive therapy plays an important role in improving the prognosis of malignant pancreatic endoc-rine tumour.展开更多
文摘I-labeled anti-CEA monoclonal antibody injected intrasplenically has better effects on inhibiting liver metastasis from human colonic adenocarcinoma than that through tail vein in nu/nu mice model.
文摘Objective To summarize our experience in the diagnosis and treatment of malignant pancreatic endocrine tumour. Methods We retrospectively reviewed 36 cases of malignant pancreatic endocrine tumours in our hospital from July 1987 to April 2002, and summarized its clinical features. Results Liver metastasis was the main malignant manifestation of malignant pancreatic endocrine tumours (incidence rate 72.2%). Removals of primary lesion and isolated hepatic metastatic lesion were means of curative therapy. Interventional chemotherapy was an important adjuvant treatment. Conclusion Comprehensive therapy plays an important role in improving the prognosis of malignant pancreatic endoc-rine tumour.
